ArticleJAAD international2026

A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.

Kamelia Vekovska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.